Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.20210217161500
Cytocom to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week 2021”20201222073500
Cytocom, Inc. Issues Shareholder Letter20201021083000
Cytocom, Inc. Issues Shareholder Letter
October 21, 2020
Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement20201019160500
Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement
October 19, 2020
Cleveland BioLabs Closes $3.175 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules20200603160500
Cleveland BioLabs Announces $3.175 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules20200601083000
Cleveland BioLabs Reports First Quarter 2020 Financial Results and Development Progress20200515090000
Cleveland BioLabs Reports Third Quarter 2019 Financial Results and Development Progress20191114163000
Cleveland Biolabs Reports Second Quarter 2019 Financial Results and Development Progress20190814083000
Cleveland Biolabs Reports First Quarter 2019 Financial Results and Development Progress20190515083000